All past issues
Bremelanotide, the FDA-approved peptide for female desire, and what Vyleesi's commercial story actually looks like
Melanotan II, the tanning peptide that rewrote sexual pharmacology, and why grey-market vials are a different animal
MOTS-c, the mitochondrial peptide sold as "exercise in a bottle," and what the humans data actually shows
CJC-1295, the weekly-injection GH booster, and the Phase II trial that ended in a fatal heart attack
Ipamorelin, the "cleanest" GH booster, and the two Phase II trials that quietly missed their endpoints
Sermorelin, the FDA-approved peptide you can't buy, and what that tells you about this market
Vilon, a two-amino-acid "longevity peptide," and why mouse lifespan doesn't equal human lifespan
DSIP, the "sleep peptide" that still can't tell you how it works
Pinealon, the "bioregulator" tradition, and why Western researchers keep raising an eyebrow
Semax, the nootropic pitch versus the stroke-rehab reality, and why the gap matters
Selank, the Russian nasal spray pitched as a gentler benzo, and what "gentler" actually means here
BPC-157, the recovery peptide everyone's heard of, and the missing human trials nobody talks about
GHK-Cu's skincare receipts, the longevity-injection detour, and where the evidence actually ends
IGF-1 LR3, the peptide too dangerous for human trials, and why the grey market sells it anyway
TB-500's marketing problem, the thymosin beta-4 name game, and what the human trials actually say